Literature DB >> 33504534

Moyamoya angiopathy unmasking systemic lupus erythematosus.

Shambaditya Das1, Souvik Dubey2, Alak Pandit1, Biman Kanti Ray1.   

Abstract

A 47-year-old woman with history of seizure disorder (semiology of seizure unknown), not well controlled with antiepileptic drugs since last 30 years presented with 1-year history of intermittent throbbing headache. On the day prior to admission, she experienced worst headache, followed by loss of consciousness. On regaining consciousness, she had neck pain without any focal neurological deficit, but examination was marked by positive meningeal signs. She had history of oral ulceration, photosensitivity and small joints pain for which no medical consultancy was sought until. Following relevant investigations, this case came out to be moyamoya angiopathy secondary to underlying systemic lupus erythematosus. She was put on immunosuppressive and immunomodulator as per recommendations. Among neurological symptoms, headache improved dramatically without any further seizure recurrence till the 6 months of follow-up. © BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  epilepsy and seizures; headache (including migraines); neuroimaging; stroke; systemic lupus erythematosus

Year:  2021        PMID: 33504534      PMCID: PMC7843324          DOI: 10.1136/bcr-2020-239307

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  2 in total

1.  Impact of COVID-19 pandemic in natural course of Moyamoya Angiopathy: an experience from tertiary-care-center in India.

Authors:  Shambaditya Das; Biman Kanti Ray; Ritwik Ghosh; Samya Sengupta; Alak Pandit; Souvik Dubey
Journal:  Egypt J Neurol Psychiatr Neurosurg       Date:  2021-12-11

2.  Epidemiology of Moyamoya Angiopathy in Eastern India.

Authors:  Shambaditya Das; Souvik Dubey; Suman Das; Avijit Hazra; Alak Pandit; Ritwik Ghosh; Biman Kanti Ray
Journal:  Front Neurol       Date:  2022-03-04       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.